… taking ivacaftor and combined therapy. Dyspnea occurs in some patients taking lumacaftor
and … Lumacaftor is a strong inducer of CYP3A while ivacaftor is a CYP3A sensitive substrate. …

… corrector (lumacaftor) and potentiator (ivacaftor) of the cystic fibrosis … cystic fibrosis in patients
(aged ≥12 years) homozygous for the most common CFTR mutation, F508del. Lumacaftor …

… of lumacaftor/ivacaftor combination therapy was shown in two randomised controlled
trials (RCTs)—TRAFFIC and TRANSPORT—in patients with cystic fibrosis who … lumacaftor/ivacaftor …

… Outcome data were similar for the two lumacaftor–ivacaftor … was stronger for the lumacaftor
400 mg plus ivacaftor group. … of lumacaftor–ivacaftor (lumacaftor 400 mg and ivacaftor 250 mg …

… of treatment with lumacaftor–ivacaftor was associated with … and adults with cystic fibrosis
homozygous for Phe508del who … Cystic fibrosis (CF) is a genetic disease caused by mutations …

… older with cystic fibrosis homozygous for F508del-cystic fibrosis … 6–11 years with cystic
fibrosis homozygous for F508del-CFTR … of lumacaftor and ivacaftor in patients with cystic fibrosis …

… that combination lumacaftor and ivacaftor improves FEV 1 for patients with cystic fibrosis who
… These results support the further exploration of combination lumacaftor and ivacaftor as a …

… Lumacaftor/ivacaftor combination therapy has shown clinical benefits in patients with cystic
fibrosis … We aimed to assess the efficacy and safety of lumacaftor/ivacaftor therapy in these …

… , lumacaftor in combination with ivacaftor improved FEV 1 and reduced the rate of pulmonary
exacerbations in patients with cystic fibrosis … Lumacaftor–ivacaftor therapy generally had an …

… sought to evaluate lumacaftor/ivacaftor combination therapy … of multiple doses of
lumacaftor/ivacaftor over 14 days in … and tolerability of lumacaftor/ivacaftor combination therapy …